Galectin Therapeutics Inc. (GALT) financial statements and ratios from SEC XBRL: revenue $126000.00 (TTM), net margin -24473.0%, revenue growth 7.7% YoY. Income statement, balance sheet, cash flow, and valuation. First-party data.
| Revenue (TTM) | $126000.00 |
| Net Margin | -24473.0% |
| Revenue Growth (YoY) | 7.7% |
| EPS Growth (YoY) | 16.7% |
| Price / Sales | 2888.68 |
| Altman Z-Score | -32.70 (distress) |
| Sector P/E (Healthcare) | 21.7 |
GALT overview · GALT earnings · GALT KPIs · GALT investor relations · GALT ownership · GALT peers · GALT filings
Data sourced from U.S. SEC EDGAR XBRL filings. Not personalized investment advice.